Click here to get full coverage on A Look At Immunome (IMNM) Valuation After New Barclays Overweight Coverage - simplywall.st

A Look At Immunome (IMNM) Valuation After New Barclays Overweight Coverage  simplywall.st

A Look At Immunome (IMNM) Valuation After New Barclays Overweight Coverage - simplywall.st

Click here to get full coverage on Trial drug eases pain and shrinks desmoid tumors in Phase 3 study - Stock Titan

Trial drug eases pain and shrinks desmoid tumors in Phase 3 study  Stock Titan

Trial drug eases pain and shrinks desmoid tumors in Phase 3 study - Stock Titan

Click here to get full coverage on H.C. Wainwright Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $40 - 富途牛牛

H.C. Wainwright Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $40  富途牛牛

H.C. Wainwright Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $40 - 富途牛牛

Click here to get full coverage on Immunome (IMNM) Reveals Promising Results in Phase 3 Trial of Va - GuruFocus

Immunome (IMNM) Reveals Promising Results in Phase 3 Trial of Va  GuruFocus

Immunome (IMNM) Reveals Promising Results in Phase 3 Trial of Va - GuruFocus

Click here to get full coverage on Immunome (IMNM) Receives a New Rating from Barclays - The Globe and Mail

Immunome (IMNM) Receives a New Rating from Barclays  The Globe and Mail

Immunome (IMNM) Receives a New Rating from Barclays - The Globe and Mail

Click here to get full coverage on What Offers Immunome (IMNM) a Compelling Investment Opportunity? - Yahoo Finance

What Offers Immunome (IMNM) a Compelling Investment Opportunity?  Yahoo Finance

What Offers Immunome (IMNM) a Compelling Investment Opportunity? - Yahoo Finance

Click here to get full coverage on Truist Financial Initiates Immunome(IMNM.US) With Buy Rating, Announces Target Price $37 - Moomoo

Truist Financial Initiates Immunome(IMNM.US) With Buy Rating, Announces Target Price $37  Moomoo

Truist Financial Initiates Immunome(IMNM.US) With Buy Rating, Announces Target Price $37 - Moomoo

Click here to get full coverage on Insider Purchase: Director at $IMNM Buys 5,000 Shares - Quiver Quantitative

Insider Purchase: Director at $IMNM Buys 5,000 Shares  Quiver Quantitative

Insider Purchase: Director at $IMNM Buys 5,000 Shares - Quiver Quantitative

Click here to get full coverage on IMNM - Immunome Inc Stock Price and Quote - Finviz

IMNM - Immunome Inc Stock Price and Quote  Finviz

IMNM - Immunome Inc Stock Price and Quote - Finviz

Click here to get full coverage on IMNM Maintained by Truist Securities -- Price Target Raised to $37 - GuruFocus

IMNM Maintained by Truist Securities -- Price Target Raised to $37  GuruFocus

IMNM Maintained by Truist Securities -- Price Target Raised to $37 - GuruFocus

Click here to get full coverage on Assessing Immunome (IMNM) Valuation After Varegacestat NDA And Phase 3 Desmoid Tumor Success - Yahoo Finance

Assessing Immunome (IMNM) Valuation After Varegacestat NDA And Phase 3 Desmoid Tumor Success  Yahoo Finance

Assessing Immunome (IMNM) Valuation After Varegacestat NDA And Phase 3 Desmoid Tumor Success - Yahoo Finance

Click here to get full coverage on Does Barclays’ Bullish Stance Refocus Immunome’s (IMNM) Investment Narrative on Its ADC Platform? - simplywall.st

Does Barclays’ Bullish Stance Refocus Immunome’s (IMNM) Investment Narrative on Its ADC Platform?  simplywall.st

Does Barclays’ Bullish Stance Refocus Immunome’s (IMNM) Investment Narrative on Its ADC Platform? - simplywall.st

Click here to get full coverage on IMNM Initiates Coverage On Barclays -- Rating Set to Overweight - GuruFocus

IMNM Initiates Coverage On Barclays -- Rating Set to Overweight  GuruFocus

IMNM Initiates Coverage On Barclays -- Rating Set to Overweight - GuruFocus

Click here to get full coverage on Immunome, Inc. (IMNM) Reports Submission of an NDA for Varegacestat in Desmoid Tumors - Yahoo Finance

Immunome, Inc. (IMNM) Reports Submission of an NDA for Varegacestat in Desmoid Tumors  Yahoo Finance

Immunome, Inc. (IMNM) Reports Submission of an NDA for Varegacestat in Desmoid Tumors - Yahoo Finance

Click here to get full coverage on Immunome (IMNM) to Present at Goldman Sachs Global Healthcare Co - GuruFocus

Immunome (IMNM) to Present at Goldman Sachs Global Healthcare Co  GuruFocus

Immunome (IMNM) to Present at Goldman Sachs Global Healthcare Co - GuruFocus

Click here to get full coverage on Immunome, Inc. (IMNM) Sets Sights on $1B Opportunity amid Pipeline Development - Yahoo Finance

Immunome, Inc. (IMNM) Sets Sights on $1B Opportunity amid Pipeline Development  Yahoo Finance

Immunome, Inc. (IMNM) Sets Sights on $1B Opportunity amid Pipeline Development - Yahoo Finance

Click here to get full coverage on Is Immunome, Inc. (IMNM) The Best Booming Stock To Buy Right Now? - Yahoo Finance

Is Immunome, Inc. (IMNM) The Best Booming Stock To Buy Right Now?  Yahoo Finance

Is Immunome, Inc. (IMNM) The Best Booming Stock To Buy Right Now? - Yahoo Finance

Click here to get full coverage on A Look At Immunome (IMNM) Valuation As Varegacestat Nears ASCO 2026 Spotlight And FDA NDA Filing - Yahoo Finance

A Look At Immunome (IMNM) Valuation As Varegacestat Nears ASCO 2026 Spotlight And FDA NDA Filing  Yahoo Finance

A Look At Immunome (IMNM) Valuation As Varegacestat Nears ASCO 2026 Spotlight And FDA NDA Filing - Yahoo Finance

Click here to get full coverage on Barclays initiates coverage of Immunome (IMNM) with overweight recommendation - MSN

Barclays initiates coverage of Immunome (IMNM) with overweight recommendation  MSN

Barclays initiates coverage of Immunome (IMNM) with overweight recommendation - MSN

Click here to get full coverage on Assessing Immunome (IMNM) Valuation After Recent Share Price Momentum And Conflicting P/B And DCF Signals - Yahoo Finance

Assessing Immunome (IMNM) Valuation After Recent Share Price Momentum And Conflicting P/B And DCF Signals  Yahoo Finance

Assessing Immunome (IMNM) Valuation After Recent Share Price Momentum And Conflicting P/B And DCF Signals - Yahoo Finance

Click here to get full coverage on Immunome (IMNM) Moves 13.3% Higher: Will This Strength Last? - Yahoo Finance

Immunome (IMNM) Moves 13.3% Higher: Will This Strength Last?  Yahoo Finance

Immunome (IMNM) Moves 13.3% Higher: Will This Strength Last? - Yahoo Finance

Click here to get full coverage on Immunome (IMNM) Is Up 11.7% After Phase 3 Varegacestat Success - Has The Bull Case Changed? - Yahoo Finance

Immunome (IMNM) Is Up 11.7% After Phase 3 Varegacestat Success - Has The Bull Case Changed?  Yahoo Finance

Immunome (IMNM) Is Up 11.7% After Phase 3 Varegacestat Success - Has The Bull Case Changed? - Yahoo Finance

Click here to get full coverage on IMNM Financials: Income Statement, Balance Sheet & Cash Flow | Immunome Inc - Stock Titan

IMNM Financials: Income Statement, Balance Sheet & Cash Flow | Immunome Inc  Stock Titan

IMNM Financials: Income Statement, Balance Sheet & Cash Flow | Immunome Inc - Stock Titan

Click here to get full coverage on Immunome Says Varegacestat Treatment Resulted In Statistically Significant Improvements In Primary And All Key Secondary Efficacy Endpoints - TradingView

Immunome Says Varegacestat Treatment Resulted In Statistically Significant Improvements In Primary And All Key Secondary Efficacy Endpoints  TradingView

Immunome Says Varegacestat Treatment Resulted In Statistically Significant Improvements In Primary And All Key Secondary Efficacy Endpoints - TradingView

Click here to get full coverage on Immunome to Present at the Goldman Sachs 47th Annual Global Healthcare Conference - Business Wire

Immunome to Present at the Goldman Sachs 47th Annual Global Healthcare Conference  Business Wire

Immunome to Present at the Goldman Sachs 47th Annual Global Healthcare Conference - Business Wire

Click here to get full coverage on Did Reduced 2025 Losses and NDA Plans Just Shift Immunome's (IMNM) Investment Narrative? - Yahoo Finance

Did Reduced 2025 Losses and NDA Plans Just Shift Immunome's (IMNM) Investment Narrative?  Yahoo Finance

Did Reduced 2025 Losses and NDA Plans Just Shift Immunome's (IMNM) Investment Narrative? - Yahoo Finance

Click here to get full coverage on Director Bienaime adds 5,000 Immunome (IMNM) shares in open-market buy - Stock Titan

Director Bienaime adds 5,000 Immunome (IMNM) shares in open-market buy  Stock Titan

Director Bienaime adds 5,000 Immunome (IMNM) shares in open-market buy - Stock Titan

Click here to get full coverage on T. Rowe Price (IMNM) files 13G/A showing 16.36M shares (14.5%) - Stock Titan

T. Rowe Price (IMNM) files 13G/A showing 16.36M shares (14.5%)  Stock Titan

T. Rowe Price (IMNM) files 13G/A showing 16.36M shares (14.5%) - Stock Titan

Click here to get full coverage on Immunome (IMNM) Valuation After Breakthrough Phase 3 RINGSIDE Results and Planned FDA New Drug Application - Yahoo Finance

Immunome (IMNM) Valuation After Breakthrough Phase 3 RINGSIDE Results and Planned FDA New Drug Application  Yahoo Finance

Immunome (IMNM) Valuation After Breakthrough Phase 3 RINGSIDE Results and Planned FDA New Drug Application - Yahoo Finance

Click here to get full coverage on Point72 and Steven A. Cohen report 0% ownership in Immunome (IMNM) - Stock Titan

Point72 and Steven A. Cohen report 0% ownership in Immunome (IMNM)  Stock Titan

Point72 and Steven A. Cohen report 0% ownership in Immunome (IMNM) - Stock Titan

Click here to get full coverage on Redmile Group and Jeremy C. Green disclose 4.9% stake in Immunome (IMNM) - Stock Titan

Redmile Group and Jeremy C. Green disclose 4.9% stake in Immunome (IMNM)  Stock Titan

Redmile Group and Jeremy C. Green disclose 4.9% stake in Immunome (IMNM) - Stock Titan

Click here to get full coverage on Sirenia Capital reports 6.1% stake in Immunome (NASDAQ: IMNM) via Schedule 13G - Stock Titan

Sirenia Capital reports 6.1% stake in Immunome (NASDAQ: IMNM) via Schedule 13G  Stock Titan

Sirenia Capital reports 6.1% stake in Immunome (NASDAQ: IMNM) via Schedule 13G - Stock Titan

Click here to get full coverage on Insider Sale: Director at $IMNM Sells 36,800 Shares - Quiver Quantitative

Insider Sale: Director at $IMNM Sells 36,800 Shares  Quiver Quantitative

Insider Sale: Director at $IMNM Sells 36,800 Shares - Quiver Quantitative

Click here to get full coverage on Immunome Reports First Quarter 2026 Financial Results and Provides Business Update - Business Wire

Immunome Reports First Quarter 2026 Financial Results and Provides Business Update  Business Wire

Immunome Reports First Quarter 2026 Financial Results and Provides Business Update - Business Wire

Click here to get full coverage on $IMNM stock is up 4% today. Here's what we see in our data. - Quiver Quantitative

$IMNM stock is up 4% today. Here's what we see in our data.  Quiver Quantitative

$IMNM stock is up 4% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Biotech Immunome to face investors at two March conferences - Stock Titan

Biotech Immunome to face investors at two March conferences  Stock Titan

Biotech Immunome to face investors at two March conferences - Stock Titan

Click here to get full coverage on Assessing Immunome (IMNM) Valuation As Premium P/B And DCF Signals Point In Different Directions - simplywall.st

Assessing Immunome (IMNM) Valuation As Premium P/B And DCF Signals Point In Different Directions  simplywall.st

Assessing Immunome (IMNM) Valuation As Premium P/B And DCF Signals Point In Different Directions - simplywall.st

Click here to get full coverage on A once-daily tumor drug reaches FDA after cutting progression risk 84% - Stock Titan

A once-daily tumor drug reaches FDA after cutting progression risk 84%  Stock Titan

A once-daily tumor drug reaches FDA after cutting progression risk 84% - Stock Titan

Click here to get full coverage on (IMNM) Movement as an Input in Quant Signal Sets - Stock Traders Daily

(IMNM) Movement as an Input in Quant Signal Sets  Stock Traders Daily

(IMNM) Movement as an Input in Quant Signal Sets - Stock Traders Daily

Click here to get full coverage on Immunome (IMNM) CEO adds 25,450 shares in $19.67 stock purchase - Stock Titan

Immunome (IMNM) CEO adds 25,450 shares in $19.67 stock purchase  Stock Titan

Immunome (IMNM) CEO adds 25,450 shares in $19.67 stock purchase - Stock Titan

Click here to get full coverage on Immunome, Inc. (IMNM) Reports Submission of an NDA for Varegacestat in Desmoid Tumors - Insider Monkey

Immunome, Inc. (IMNM) Reports Submission of an NDA for Varegacestat in Desmoid Tumors  Insider Monkey

Immunome, Inc. (IMNM) Reports Submission of an NDA for Varegacestat in Desmoid Tumors - Insider Monkey

Click here to get full coverage on Seven new Immunome hires get options on 282,000 shares - Stock Titan

Seven new Immunome hires get options on 282,000 shares  Stock Titan

Seven new Immunome hires get options on 282,000 shares - Stock Titan

Click here to get full coverage on Immunome: Upcoming NDA, Valuation, And Investment Case (NASDAQ:IMNM) - Seeking Alpha

Immunome: Upcoming NDA, Valuation, And Investment Case (NASDAQ:IMNM)  Seeking Alpha

Immunome: Upcoming NDA, Valuation, And Investment Case (NASDAQ:IMNM) - Seeking Alpha

Click here to get full coverage on Why is IMNM stock rising today? - MSN

Why is IMNM stock rising today? - MSN

Click here to get full coverage on Will Immunome's (IMNM) Antibody Collaboration Refocus Its Pipeline Expansion Strategy? - Yahoo Finance

Will Immunome's (IMNM) Antibody Collaboration Refocus Its Pipeline Expansion Strategy?  Yahoo Finance

Will Immunome's (IMNM) Antibody Collaboration Refocus Its Pipeline Expansion Strategy? - Yahoo Finance

Click here to get full coverage on Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)  Business Wire

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Click here to get full coverage on Bienaime buys Immunome (IMNM) shares worth $43,670 - Investing.com

Bienaime buys Immunome (IMNM) shares worth $43,670  Investing.com

Bienaime buys Immunome (IMNM) shares worth $43,670 - Investing.com

Click here to get full coverage on Jim Cramer on Immunome: “If You Want to Speculate on It, Fine” - Yahoo Finance

Jim Cramer on Immunome: “If You Want to Speculate on It, Fine”  Yahoo Finance

Jim Cramer on Immunome: “If You Want to Speculate on It, Fine” - Yahoo Finance

Click here to get full coverage on Craig-Hallum Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $36 - Moomoo

Craig-Hallum Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $36  Moomoo

Craig-Hallum Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $36 - Moomoo

Click here to get full coverage on Liquidity Mapping Around (IMNM) Price Events - Stock Traders Daily

Liquidity Mapping Around (IMNM) Price Events  Stock Traders Daily

Liquidity Mapping Around (IMNM) Price Events - Stock Traders Daily

Click here to get full coverage on How Immunome’s (IMNM) Varegacestat NDA and Phase 3 Data Could Reshape Its Desmoid Tumor Story - simplywall.st

How Immunome’s (IMNM) Varegacestat NDA and Phase 3 Data Could Reshape Its Desmoid Tumor Story  simplywall.st

How Immunome’s (IMNM) Varegacestat NDA and Phase 3 Data Could Reshape Its Desmoid Tumor Story - simplywall.st

Click here to get full coverage on Immunome (Nasdaq: IMNM) posts 84% risk cut in Phase 3 desmoid tumor trial - Stock Titan

Immunome (Nasdaq: IMNM) posts 84% risk cut in Phase 3 desmoid tumor trial  Stock Titan

Immunome (Nasdaq: IMNM) posts 84% risk cut in Phase 3 desmoid tumor trial - Stock Titan

Click here to get full coverage on Immunome Inc. Stock (IMNM) Opinions on Phase 3 RINGSIDE Trial Results - Quiver Quantitative

Immunome Inc. Stock (IMNM) Opinions on Phase 3 RINGSIDE Trial Results  Quiver Quantitative

Immunome Inc. Stock (IMNM) Opinions on Phase 3 RINGSIDE Trial Results - Quiver Quantitative

Click here to get full coverage on Biotech investors: Immunome joins Guggenheim summit lineup - Stock Titan

Biotech investors: Immunome joins Guggenheim summit lineup  Stock Titan

Biotech investors: Immunome joins Guggenheim summit lineup - Stock Titan

Click here to get full coverage on Immunome (NASDAQ: IMNM) CSO gifts 6,291 shares, retains 31,438 - Stock Titan

Immunome (NASDAQ: IMNM) CSO gifts 6,291 shares, retains 31,438  Stock Titan

Immunome (NASDAQ: IMNM) CSO gifts 6,291 shares, retains 31,438 - Stock Titan

Click here to get full coverage on Why Is IMNM Stock Rising Today? - Stocktwits

Why Is IMNM Stock Rising Today?  Stocktwits

Why Is IMNM Stock Rising Today? - Stocktwits

Click here to get full coverage on Immunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors - Yahoo Finance

Immunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors  Yahoo Finance

Immunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors - Yahoo Finance

Click here to get full coverage on Don't Ignore The Insider Selling In Immunome - simplywall.st

Don't Ignore The Insider Selling In Immunome  simplywall.st

Don't Ignore The Insider Selling In Immunome - simplywall.st

Click here to get full coverage on Immunome Chairman Acquires 5.8% More Stock - Yahoo Finance

Immunome Chairman Acquires 5.8% More Stock  Yahoo Finance

Immunome Chairman Acquires 5.8% More Stock - Yahoo Finance

Click here to get full coverage on What Do Recent Insider Sales at Immunome (IMNM) Signal - Kavout

What Do Recent Insider Sales at Immunome (IMNM) Signal  Kavout

What Do Recent Insider Sales at Immunome (IMNM) Signal - Kavout

Click here to get full coverage on Why Immunome Stock Surged Today - Yahoo Finance

Why Immunome Stock Surged Today  Yahoo Finance

Why Immunome Stock Surged Today - Yahoo Finance

Click here to get full coverage on Clinical-pathologic classification of anti-HMGCR-positive immune-mediated necrotizing myopathy - Nature

Clinical-pathologic classification of anti-HMGCR-positive immune-mediated necrotizing myopathy  Nature

Clinical-pathologic classification of anti-HMGCR-positive immune-mediated necrotizing myopathy - Nature

Click here to get full coverage on Immunome Inc (IMNM) CSO Higgins sells $204,238 in stock - Investing.com

Immunome Inc (IMNM) CSO Higgins sells $204,238 in stock  Investing.com

Immunome Inc (IMNM) CSO Higgins sells $204,238 in stock - Investing.com

Click here to get full coverage on Immunome (IMNM) Price Forecast: Breakout Points to Higher Highs Ahead - FXEmpire

Immunome (IMNM) Price Forecast: Breakout Points to Higher Highs Ahead  FXEmpire

Immunome (IMNM) Price Forecast: Breakout Points to Higher Highs Ahead - FXEmpire

Click here to get full coverage on Immunome (IMNM) Shares Surge Over 30% Following Phase 3 Data - GuruFocus

Immunome (IMNM) Shares Surge Over 30% Following Phase 3 Data  GuruFocus

Immunome (IMNM) Shares Surge Over 30% Following Phase 3 Data - GuruFocus

Click here to get full coverage on Immunome Desmoid Tumor Data And NDA Plan Test Growth Expectations - simplywall.st

Immunome Desmoid Tumor Data And NDA Plan Test Growth Expectations  simplywall.st

Immunome Desmoid Tumor Data And NDA Plan Test Growth Expectations - simplywall.st

Click here to get full coverage on Immunome's Chief Scientist Trimmed His Stake. A Planned FDA Submission Tells You More - The Motley Fool

Immunome's Chief Scientist Trimmed His Stake. A Planned FDA Submission Tells You More  The Motley Fool

Immunome's Chief Scientist Trimmed His Stake. A Planned FDA Submission Tells You More - The Motley Fool

Click here to get full coverage on Immunome, Inc. Common Stock (IMNM) Stock Price Today & Analysis - Gotrade

Immunome, Inc. Common Stock (IMNM) Stock Price Today & Analysis  Gotrade

IMNM

Price Chart

Key Statistics

Technicals

About IMNM

Latest News

A Look At Immunome (IMNM) Valuation After New Barclays Overweight Coverage - simplywall.st

Trial drug eases pain and shrinks desmoid tumors in Phase 3 study - Stock Titan

H.C. Wainwright Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $40 - 富途牛牛

Advanced Charts

Top Gainers

Top Losers